JP5683488B2 - ピリダジノン誘導体 - Google Patents

ピリダジノン誘導体 Download PDF

Info

Publication number
JP5683488B2
JP5683488B2 JP2011544797A JP2011544797A JP5683488B2 JP 5683488 B2 JP5683488 B2 JP 5683488B2 JP 2011544797 A JP2011544797 A JP 2011544797A JP 2011544797 A JP2011544797 A JP 2011544797A JP 5683488 B2 JP5683488 B2 JP 5683488B2
Authority
JP
Japan
Prior art keywords
formula
compounds
het
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011544797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514612A (ja
Inventor
ディーター ドルシュ、
ディーター ドルシュ、
オリヴァー シャット、
オリヴァー シャット、
フランク シュティーバー、
フランク シュティーバー、
アンドレー ブラウカート、
アンドレー ブラウカート、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2012514612A publication Critical patent/JP2012514612A/ja
Application granted granted Critical
Publication of JP5683488B2 publication Critical patent/JP5683488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011544797A 2009-01-08 2009-12-10 ピリダジノン誘導体 Active JP5683488B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009004061.7 2009-01-08
DE102009004061A DE102009004061A1 (de) 2009-01-08 2009-01-08 Pyridazinonderivate
PCT/EP2009/008839 WO2010078909A1 (de) 2009-01-08 2009-12-10 Pyridazinonderivate

Publications (2)

Publication Number Publication Date
JP2012514612A JP2012514612A (ja) 2012-06-28
JP5683488B2 true JP5683488B2 (ja) 2015-03-11

Family

ID=41581157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011544797A Active JP5683488B2 (ja) 2009-01-08 2009-12-10 ピリダジノン誘導体

Country Status (24)

Country Link
US (1) US8623870B2 (hr)
EP (1) EP2373647B1 (hr)
JP (1) JP5683488B2 (hr)
KR (1) KR101669696B1 (hr)
CN (1) CN102272131A (hr)
AR (1) AR074997A1 (hr)
AU (1) AU2009336851B2 (hr)
BR (1) BRPI0923903B8 (hr)
CA (1) CA2749015C (hr)
CY (1) CY1113700T1 (hr)
DE (1) DE102009004061A1 (hr)
DK (1) DK2373647T3 (hr)
EA (1) EA020574B1 (hr)
ES (1) ES2398023T3 (hr)
HR (1) HRP20120976T1 (hr)
IL (1) IL213826A (hr)
MX (1) MX2011007209A (hr)
PL (1) PL2373647T3 (hr)
PT (1) PT2373647E (hr)
SG (1) SG172458A1 (hr)
SI (1) SI2373647T1 (hr)
SM (1) SMT201300010B (hr)
WO (1) WO2010078909A1 (hr)
ZA (1) ZA201105781B (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
IL115889A0 (en) 1994-11-14 1996-01-31 Rohm & Haas Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
HUP0100059A3 (en) 1997-11-19 2002-08-28 Kowa Co Novel pyridazine derivatives and drugs containing the same as the active ingredient
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
AU2001266233B2 (en) 2000-07-07 2006-06-29 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
CZ2004516A3 (cs) 2001-10-31 2004-08-18 Merckápatentágmbh Inhibitor fosfodiesterázy typu @Ź jeho kombinace s jinými drogami a jeho použití
NZ533282A (en) 2001-12-05 2006-09-29 Ortho Mcneil Pharm Inc 6-O-Acyl ketolide derivatives of erythromycine useful as antibacterials
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗hcv作用を有する縮合ヘテロ環化合物
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
US7825137B2 (en) 2005-12-05 2010-11-02 Pfizer Inc. Method of treating abnormal cell growth
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
CL2008000066A1 (es) * 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
WO2010075068A1 (en) * 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
DE102009003954A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate

Also Published As

Publication number Publication date
EA201101038A1 (ru) 2012-01-30
PT2373647E (pt) 2013-01-30
AR074997A1 (es) 2011-03-02
JP2012514612A (ja) 2012-06-28
CY1113700T1 (el) 2016-06-22
DE102009004061A1 (de) 2010-07-15
EP2373647B1 (de) 2012-10-31
PL2373647T3 (pl) 2013-03-29
EP2373647A1 (de) 2011-10-12
ZA201105781B (en) 2012-04-25
SMT201300010B (it) 2013-03-08
CN102272131A (zh) 2011-12-07
WO2010078909A1 (de) 2010-07-15
CA2749015C (en) 2017-10-31
DK2373647T3 (da) 2012-12-10
IL213826A (en) 2016-07-31
BRPI0923903A2 (pt) 2015-07-28
BRPI0923903B1 (pt) 2020-03-24
US20110269771A1 (en) 2011-11-03
KR20110099799A (ko) 2011-09-08
EA020574B1 (ru) 2014-12-30
CA2749015A1 (en) 2010-07-15
AU2009336851B2 (en) 2016-03-03
SG172458A1 (en) 2011-08-29
BRPI0923903B8 (pt) 2021-05-25
US8623870B2 (en) 2014-01-07
HRP20120976T1 (hr) 2012-12-31
ES2398023T3 (es) 2013-03-13
MX2011007209A (es) 2011-08-04
AU2009336851A1 (en) 2011-08-25
SI2373647T1 (sl) 2013-01-31
KR101669696B1 (ko) 2016-10-27
IL213826A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
JP5210172B2 (ja) 腫瘍治療用のピリジアジノン誘導体
JP5443381B2 (ja) Metキナーゼ阻害剤としての2−ベンジルピリダジノン誘導体
JP5662325B2 (ja) アザインドール誘導体
JP5485875B2 (ja) ピリダジノン誘導体
JP5385262B2 (ja) アリールエーテルピリダジノン誘導体
JP5576358B2 (ja) ピリダジノン誘導体
JP5662143B2 (ja) 腫瘍の処置のためのMetキナーゼ阻害剤としての2−オキソ−3−ベンジルベンゾキサゾール−2−オン誘導体、および関連する化合物
JP5475778B2 (ja) 腫瘍の治療のための二環式トリアゾール誘導体
JP5174665B2 (ja) 1−アシルジヒドロピラゾール誘導体
JP5592395B2 (ja) ピリダジノン誘導体
JP5662311B2 (ja) Metキナーゼ阻害剤としての3−(3−ピリミジン−2−イルベンジル)−1,2,4−トリアゾロ[4,3−b]ピリダジン誘導体
JP2010536719A (ja) 6−チオキソピリダジン誘導体
JP5334586B2 (ja) 置換5−フェニル−3,6−ジヒドロ−2−オキソ−6h−[1,3,4]チアジアジン
KR101674695B1 (ko) 피리다지논 유도체
JP5653933B2 (ja) ベンゾチアゾロン誘導体
JP5576395B2 (ja) 3−(3−ピリミジン−2−イルベンジル)−1,2,4−トリアゾロ[4,3−a]ピリミジン誘導体
JP5643192B2 (ja) 腫瘍を処置するためのチロシンキナーゼモジュレーターとしてのジヒドロピラゾール誘導体
JP5524840B2 (ja) チアジアジノン誘導体
JP5683488B2 (ja) ピリダジノン誘導体
JP5497783B2 (ja) 3−(3−ピリミジン−2−イルベンジル)−1,2,4−トリアゾロ[4,3−b]ピリダジン誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150113

R150 Certificate of patent or registration of utility model

Ref document number: 5683488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250